Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
Clinical trial NCT07311577 · RECRUITING
Trial details
- NCT number
- NCT07311577
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2027-12-30
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.